Search the Newsreel

Medicamen Biotech Q1 Results: Net profit up 54% YoY to ₹252.69 lakh

PDS Biotechnology shareholders approve charter amendment and director elections

PDS Biotechnology Corporation shareholders have approved an amendment to the company's certificate of incorporation, increasing the number of authorized common shares from 150 million to 300 million. They also elected two Class B directors, Kamil Ali-Jackson and Ilian Iliev, and ratified KPMG US LLP …

Medicamen Biotech consolidated net profit declines 1.40% in the June 2026 quarter

KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism

Moleculin Biotech GAAP EPS of -$1.40 misses by $0.53

* Moleculin Biotech press release [https://seekingalpha.com/pr/20619725-moleculin-biotech-reports-second-quarter-2026-financial-results-and-highlights-continued] (MBRX [https://seekingalpha.com/symbol/MBRX]): Q2 GAAP EPS of -$1.40 misses by $0.53. * As of June 30, 2026, the company had cash and cash equivalents of approximately $7.3 million. Management believes that its cash on hand and cash equivalents as …

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

Moleculin Biotech reported its second-quarter 2026 financial results, highlighting significant progress in its pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory AML. Positive interim data showed complete remission rates three times higher than the control group, with enrollment on track for …

Evaxion (NASDAQ: EVAX) sets August 20 call for Q2 2026 results and update

PDS Biotechnology (PDSB) wins approval to double authorized stock and elect directors

PDS Biotechnology Corporation announced that its stockholders approved an amendment to increase the authorized common stock from 150,000,000 to 300,000,000 shares. Additionally, stockholders elected Kamil Ali-Jackson, J.D. and Ilian Iliev, Ph.D. as Class B directors to serve until the 2029 annual meeting. The meeting …

Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026

Evaxion COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will provide a business update and report its second quarter 2026 financial results on Thursday August 20, 2026, before opening …

Windlas Biotech Q1FY27 revenue hits record ₹248 crore, up 18%

Windlas Biotech Share Price Target 2027 to 2030: Analyst Outlook

Panacea Biotec Publishes Q1 FY2026 Unaudited Results in Newspapers

Beijing Luzhu Biotechnology Sets Board Meeting to Review Interim Results

Touyun Biotech Sets Board Meeting to Review Interim Results and Dividend

Viva Biotech Sets Board Meeting to Approve Interim Results and Mull Dividend

Dimensional Fund Advisors LP Cuts Stock Holdings in Adaptive Biotechnologies Corporation $ADPT

Dimensional Fund Advisors LP significantly reduced its stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 86.4% in the first quarter, selling over 1.19 million shares and retaining 188,338 shares. Despite this, institutional investors still hold 99.17% of the stock. Adaptive Biotechnologies reported a 21.5% increase …

RTW Biotech Opportunities reports July NAV at $2.82 per share By Investing.com

RBC Initiates Krystal Biotech at Outperform, With $400 Price Target

RBC Capital Markets has initiated coverage on Krystal Biotech with an Outperform rating and a $400 price target, citing strong positioning for future gains from its product VYJUVEK and a promising pipeline. The biotech company, which specializes in genetic medicines, recently reported Q2 2026 …

Burning Rock Biotech (NASDAQ:BNR) Stock Price Down 3.7% - What's Next?

XBiotech (NASDAQ:XBIT) Issues Quarterly Earnings Results, Misses Estimates By $0.25 EPS

XBiotech (NASDAQ:XBIT) reported a quarterly loss of $0.22 per share, significantly missing analysts' consensus estimate of a $0.03 profit by $0.25. Following the announcement, XBIT shares fell by $0.13 to $2.33, nearing its 52-week low, and the company's market capitalization is approximately $71 million. …

Form 8K EDESA BIOTECH For: 13 August By Investing.com

This article reports that EDESA BIOTECH filed a Form 8K on August 13th, as tracked by Investing.com. The filing details are not provided within the article itself, but it highlights the company EDSA with a stock performance of +2.45%. The piece is primarily a …

Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Co-Founder, President and Chief Executive Officer - Claude MaraouiChief Financial Officer - Joseph BeneschChief Operating Officer and General Counsel - Ramsey AlloushSenior Director of Corporate Operations - Jaclyn …

RTW Biotech Opportunities Ltd USD Revenue Breakdown – GETTEX:0BM

Edesa Biotech (NASDAQ:EDSA) Posts Earnings Results, Misses Expectations By $0.16 EPS

Edesa Biotech (NASDAQ:EDSA) reported a quarterly loss of $0.60 per share, missing analyst expectations by $0.16. Shares traded up $0.13 to $5.43, with a highly volatile one-year range of $0.72 to $20.32. Institutional investors own 5.50% of the stock, and analyst ratings are mixed, …

Fortress Biotech earnings beat by $0.11, revenue fell short of estimates

Fortress Biotech (NASDAQ:FBIO) Posts Earnings Results, Beats Estimates By $0.12 EPS

Fortress Biotech (NASDAQ:FBIO) announced its quarterly earnings, reporting an adjusted loss of $0.08 per share, surpassing the consensus estimate by $0.12. The biopharmaceutical company also exceeded revenue forecasts with $18.72 million. Despite mixed analyst sentiment and a "Hold" consensus rating, institutional investors own a …

Edesa Biotech Inc reports results for the quarter ended June 30 - Earnings Summary

Edesa Biotech Inc has reported its earnings for the quarter that ended on June 30. The article provides a summary of these results. To access the full details, readers are directed to the complete article available through TradingView, which offers unlimited access to Reuters …

Fortress Biotech 2026: Revenue $17.84M, Net income ($2.48M), EPS ($0.08) — 10-Q Summary

Fortress Biotech (FBIO) reported its financial results for the quarter ended in 2026, showing product revenue of $17.84 million, an 18.9% increase year-over-year. Despite the revenue growth, the company recorded a net loss attributable to common stockholders of ($2.48 million) and a diluted loss …

Edesa Biotech Q3 Results: EPS misses estimate, losses widen 140% YoY

Fortress Biotech: Q2 Earnings Snapshot

Moleculin Biotech (NASDAQ: MBRX) advances AML trial but warns on cash

Moleculin Biotech (NASDAQ: MBRX) is progressing with its pivotal Phase 2/3 MIRACLE trial for Annamycin in relapsed/refractory AML, showing promising preliminary efficacy and cardiac safety data. Despite these clinical advancements and a recent $9.3 million equity/warrant offering, the company reported a net loss of …

Edesa Biotech (EDSA) loss widens to $11.9M as R&D surges and cash tightens

Fortress Biotech (NASDAQ: FBIO) gains $158.9M from voucher sale and boosts cash

Edesa Reports $5.4 Million Q3 Loss as EB06 Phase 2 Site Activation Begins

Edesa Biotech (EDSA) reported a net loss of $5.4 million for Q3 2026, an increase from $1.7 million in the prior year, primarily due to rising operating expenses from its Phase 2 EB06 vitiligo study. The company is beginning site activation for this study …

Moleculin Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

Edesa Biotech (Nasdaq: EDSA) reported its fiscal third-quarter 2026 results, showing a net loss of $5.4 million due to increased operating expenses. The company announced it has completed preparations for its Phase 2 EB06 vitiligo trial and begun activating initial investigational sites, with patient …